TEL AVIV, ISRAEL, October 31, 2022 /24-7PressRelease/ —

• Squalus Medical renames itself as BT BeaMedical Technologies (BeaMed)


• BeaMed moves to new offices in Caesarea Israel and receives ISO13485 certification for its new facility as part of its FDA 510(k) regulatory pathway for obtaining marketing clearance in the U.S.

Squalus Medical, a private company developing a novel laser based platform for epilepsy and cancer surgery, has decided to rebrand itself as BT BeaMedical Technologies (BeaMed) as part of its market entry strategy into the U.S. market.

BeaMed is the inventor and developer of the StingRay Laser System (the “StingRay System”), a novel laser-based thermal ablation technology designed for treatment of previously inoperable cases of epilepsy and for improvement of outcomes and enablement of new treatment options for oncology procedures, including those treating brain, prostate, liver, breast and lung cancers.

The StingRay System combines new fiber optic technology with an advanced laser console and computerized intelligent control, that allows a perfect match between the exact structure of tumors and epileptic focal points and the energy delivery, while protecting vital functional areas against thermal damage. The console integrates advanced imaging modalities, and guides the physician, making sure the treatment is adjusted to the specific patient needs with real time energy control.

“We are thrilled with the progress BeaMed is making towards developing a product that will potentially help millions of patients globally suffering from epilepsy and cancer. The rebranding of the company matches our product vision and is a first step in creating a unique and powerful brand in the surgical community,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals, BeaMed’s lead investor.

“As we move forward with development and product introduction, we wanted to create a brand which captures the essence of our technology and our unique features, including the innovative use of laser beam emission to fit the specific needs of each patient. In addition, we are happy to announce the completion of certification of the new company under ISO13485 in our new office space, the first step in our 510(k) regulatory approval strategy,” said Gil Shapira, co-founder of BeaMed.

BeaMed was founded by Moshe Eshkol and Gil Shapira, both highly experienced specialists in surgical lasers and medical devices. BeaMed and the development of the StingRay system are also supported by a special prestigious grant from the BIRD Foundation (https://www.birdf.com/), a bi-national organization supporting Israel-US collaboration. Gil Shapira brings forward 26+ years of engineering and product development and management experience, with over 17 years in the surgical laser industry. Gil owns and manages neoLaser, a company he founded in 2012, and led to revenue growth and profitability, with a 43% CAGR on its way to more than 1200 global installations and performing 50,000+ surgeries annually in over 30 countries. Previously, Gil led product development and marketing at OmniGuide, a successful high-growth laser based medical device spin-off out of the Massachusetts Institute of Technology (MIT).

Contact Information:


www.beam-med.com


[email protected]

BeaMed is the inventor and developer of the StingRay Laser System (the “StingRay System”), a novel laser-based thermal ablation technology designed for treatment of previously inoperable cases of epilepsy and for improvement of outcomes and enablement of new treatment options for oncology procedures, including those treating brain, prostate, liver, breast and lung cancers.

# # #